Download PDF
Thromb Haemost 1997; 77(05): 0975-0980
DOI: 10.1055/s-0038-1656088
Platelets
Schattauer GmbH Stuttgart

Desmopressin (DDAVP) Enhances Platelet Adhesion to the Extracellular Matrix of Cultured Human Endothelial Cells through Increased Expression of Tissue Factor

Angel Gálvez
,
Goretti Gómez-Ortiz
The Servicio de Hemoterapia y Hemostasia, Hospital Clinic, Facultad de Medicina, Barcelona, Spain
,
Maribel Díaz-Ricart
The Servicio de Hemoterapia y Hemostasia, Hospital Clinic, Facultad de Medicina, Barcelona, Spain
,
Ginés Escolar
The Servicio de Hemoterapia y Hemostasia, Hospital Clinic, Facultad de Medicina, Barcelona, Spain
,
Rogelio González-Sarmiento
1   Unidad de Genética Molecular, Departamento Medicina, Universidad de Salamanca, Salamanca, Spain
,
María J Zurbano
The Servicio de Hemoterapia y Hemostasia, Hospital Clinic, Facultad de Medicina, Barcelona, Spain
,
Antonio Ordinas
The Servicio de Hemoterapia y Hemostasia, Hospital Clinic, Facultad de Medicina, Barcelona, Spain
,
Ricardo Castillo
The Servicio de Hemoterapia y Hemostasia, Hospital Clinic, Facultad de Medicina, Barcelona, Spain
› Author Affiliations
Further Information

Publication History

Received 12 January 1996

Accepted after resubmission 22 January 1997

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effect of desmopressin (DDAVP) on thrombogenicity, expression of tissue factor and procoagulant activity (PCA) of extracellular matrix (ECM) generated by human umbilical vein endothelial cells cultures (HUVEC), was studied under different experimental conditions. HUVEC were incubated with DDAVP (1, 5 and 30 ng/ml) and then detached from their ECM. The reactivity towards platelets of this ECM was tested in a perfusion system. Coverslips covered with DD A VP-treated ECMs were inserted in a parallel-plate chamber and exposed to normal blood anticoagulated with low molecular weight heparin (Fragmin®, 20 U/ml). Perfusions were run for 5 min at a shear rate of 800 s1. Deposition of platelets on ECMs was significantly increased with respect to control ECMs when DDAVP was used at 5 and 30 ng/ml (p <0.05 and p <0.01 respectively). The increase in platelet deposition was prevented by incubation of ECMs with an antibody against human tissue factor prior to perfusion. Immunofluorescence studies positively detected tissue factor antigen on DDAVP derived ECMs. A chromogenic assay performed under standardized conditions revealed a statistically significant increase in the procoagulant activity of the ECMs produced by ECs incubated with 30 ng/ml DDAVP (p <0.01 vs. control samples). Northern blot analysis revealed increased levels of tissue factor mRNA in extracts from ECs exposed to DDAVP. Our data indicate that DDAVP in vitro enhances platelet adhesion to the ECMs through increased expression of tissue factor. A similar increase in the expression of tissue factor might contribute to the in vivo hemostatic effect of DDAVP.

 

  • References

  • 1 Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost Thromb 1986; 8: 19-45
    PubMedGoogle Scholar
  • 2 Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Rev 1991; 5: 155-161
    CrossrefPubMedGoogle Scholar
  • 3 Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. Thromb Haemost 1994; 71: 154-155
    PubMedGoogle Scholar
  • 4 Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 1994; 69: 173-180
    CrossrefPubMedGoogle Scholar
  • 5 David JL. Desmopressin and hemostasis. Regul Peptides 1993; 45: 311-317
    CrossrefPubMedGoogle Scholar
  • 6 Pfueller SL, Howard MA, White JG, Menon C, Berry EW. Shortening of bleeding time by l-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in gray platelet syndrome. Thromb Haemost 1987; 58: 1060-1063
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Cattaneo M, Moia M, DellaValle P, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitates. Evidence for a mechanism of action independent of released von willebrand factor. Blood 1989; 74: 1972-1975
    PubMedGoogle Scholar
  • 8 Watson AJS, Koegh JAB. Effect of l-deamino-8-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron 1982; 32: 49-52
    CrossrefPubMedGoogle Scholar
  • 9 Escolar G, Cases A, Monteagudo J, Garrido M, López J, Ordinas A, Revert L, Castillo R. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med 1989; 114: 36-42
    PubMedGoogle Scholar
  • 10 Johnstone MT, Andrews JA, Ware JA. Bleeding time prolongation with streptokinase and its reduction with l-deamino-8-arginine vasopressin. Circulation 1990; 82: 2142-2151
    CrossrefPubMedGoogle Scholar
  • 11 Barnhart MI, Chen S, Lusher JM. DDAVP: Does the drug have a direct effect on the vessel wall? Thromb Res. 1983; 31: 239-53
    PubMedGoogle Scholar
  • 12 Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 71: 629-635
    PubMedGoogle Scholar
  • 13 Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffmann T. Evidence for the presence of tissue factor activity on subendothelium. Blood 1989; 73: 968-975
    PubMedGoogle Scholar
  • 14 de Groot PG, Reinders JH, Sixma JJ. Perturbation of human endothelial cells by thrombin or PMA changes the reactivity of their extracellular matrix towards platelets. J Cell Biol 1987; 104: 697-704
    CrossrefPubMedGoogle Scholar
  • 15 Jaffe EA, Nachman RL, Becker CG. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1973; 52: 2745-2756
    CrossrefPubMedGoogle Scholar
  • 16 Aznar-Salatti J, Bastida E, Haas TA, Escolar G, Ordinas A, de GrootPG, Buchanan MR. Platelet adhesion to exposed endothelial cell extracellular matrices is influenced by the method of preparation. Arterioscler Thromb 1991; 11: 436-442
    CrossrefPubMedGoogle Scholar
  • 17 Fiore MM, Neuenschwander PF, Morrissey JH. An unusual antibody that blocks tissue factor/FVIIa function by inhibiting cleavage only of macro- molecular substrates. Blood 1992; 80: 3127-3134
    PubMedGoogle Scholar
  • 18 Sakariassen KS, Aarts PA, de Groot PG, Houdijk WP, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102: 522-535
    PubMedGoogle Scholar
  • 19 Diaz-Ricart M, Carretero M, Castillo R, Ordinas A, Escolar G. Digital image analysis of platelet-extracellular matrix interactions: studies in von Willebrand disease patients and aspirin-treated donors. Haemostasis 1994; 24: 219-229
    PubMedGoogle Scholar
  • 20 Ravanat C, Archipoff G, Beretz A, Freund G, Cazenave JP, Freyssinet JM. Use of annexin-V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells. Biochem J 1992; 282: 07-13
    CrossrefPubMedGoogle Scholar
  • 21 Carson SD, Johnson DR. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood 1990; 76: 361-367
    PubMedGoogle Scholar
  • 22 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159
    PubMedGoogle Scholar
  • 23 Sambrook J, Fritsch EF, Maniatis T. molecular cloning: a laboratory manual. 2. nd edit. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY, USA: 1989
    Google Scholar
  • 24 Lehrach H, Diamond D, Wozney JM, Boedtker H. RNA molecular weight determination by gel electrophoresis under denaturating conditions a critical reexamination. Biochemistry 1977; 16: 4743-4751
    CrossrefPubMedGoogle Scholar
  • 25 Bolhuis PA, Sakariassen KS, Sander HJ, Bouma BN, Sixma JJ. Binding of factor VUI-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med 1981; 97: 568-5676
    PubMedGoogle Scholar
  • 26 Sakariassen KS, Bolhuis PA, Blomback M, Thorell L, Blomback B, Sixma JJ. Association between bleeding time and platelet adherence to artery subendothelium. Thromb Haemost 1984; 52: 144-147
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Sakariassen KS, Nieuwenhuis HK, Sixma JJ. Differentiation of patients with subtype Ilb-like von Willebrand’s disease by means of perfusion experiments with reconstituted blood. Br J Haematol 1985; 59: 459-470
    CrossrefPubMedGoogle Scholar
  • 28 Sakariassen KS, Nievelstein PF, Coller BS, sixma JJ. The role of platelet membrane glycoproteins lb and Ilb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986; 63: 681-691
    CrossrefPubMedGoogle Scholar
  • 29 Sixma JJ, Nievelstein PF, Zwaginga JJ, de Groot PG. Adhesion of blood platelets to the extracellular matrix of cultured human endothelial cells. Ann NY Acad Sci 1987; 516: 39-51
    CrossrefPubMedGoogle Scholar
  • 30 Zwaginga JJ, de Boer HC, IJsseldijk MJ, Kerkhof A, Muller-Berghaus G, Gruhlichhenn J, Sixma JJ, de Groot PG. Thrombogenicity of vascular cells. Comparison between endothelial cells isolated from different sources and smooth muscle cells and fibroblasts. Arteriosclerosis 1990; 10: 437-448
    CrossrefPubMedGoogle Scholar
  • 31 Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant. Arteriosclerosis 1990; 10: 49-61
    CrossrefPubMedGoogle Scholar
  • 32 Rao LVM, Rapaport SI, Bajaj SP. Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood 1986; 65: 685-691
    PubMedGoogle Scholar
  • 33 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-1097
    PubMedGoogle Scholar
  • 34 Nawroth P, Stern D. Modulation of endothelial cell hemostatic properties by tumour necrosis factor. J Exp Med 1986; 163: 740-745
    CrossrefPubMedGoogle Scholar
  • 35 Mulder AB, Karin SM, Heggepaping KSM, Magielse CPE, Blom NR, Smit JW, Vandermeer J, Halie MR, Bom VJJ. Tumor necrosis factor α-induced endothelial tissue factor is located on the cell surface rather than in the subendothelial matrix. Blood 1994; 84: 1559-1566
    PubMedGoogle Scholar
  • 36 Colucci M, Balconi G, Lorenzet T, Petra A, Locati D. Cultures human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1896
    CrossrefPubMedGoogle Scholar
  • 37 Nemerson Y. Tissue factor and haemostasis. Blood 1988; 71: 01-08
    PubMedGoogle Scholar
  • 38 Salatti JA, Fenton J, Anton P, Sakariassen KS. α-Thrombin bound to extracellular endothelial matrix induces pronounced fibrin deposition and platelet thrombus growth in flowing non-anticoagulated human blood. Blood Coag Fibrinol 1994; 5: 561-566
    PubMedGoogle Scholar
  • 39 Orvim U, Roald HE, Stephens RW, Roos N, Sakariassen KS. Tissue factor induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow. Arterioscler Thromb 1994; 14: 1976-1983
    CrossrefPubMedGoogle Scholar
  • 40 Moffat EH, Giddings JC, Bloom AL. The effect of l-deamino-8-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Br J Haematol 1984; 57: 651-662
    CrossrefPubMedGoogle Scholar
  • 41 Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. Von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85-90
    PubMedGoogle Scholar